MAPT and Alzheimer disease: The challenges for NT therapy in animal models of AD arise mainly from the nature of AD (a chronic impairment, unique to human, of tau protein and Aβ peptides that regulate several key physiological brain processes) and from the incomplete understanding of AD’s aetiology.